NDAORALTABLET
Approved
Jul 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Trioxsalen (TRISORALEN) is an oral psoralen compound approved in 1964 for photochemotherapy applications. It is a small-molecule photosensitizing agent used in combination with UVA light exposure for dermatological indications. The drug works by intercalating into DNA and becoming activated by UVA radiation to produce therapeutic effects.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature asset with declining commercial momentum and smaller team allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRISORALEN offers limited career acceleration opportunity given its LOE-approaching status and zero linked job postings. Professionals may be involved in legacy brand stewardship, generic transition planning, or portfolio rationalization rather than growth-focused initiatives.
Brand ManagerField Sales Representative
Worked on TRISORALEN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.